Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2016)

Viridian Therapeutics, Inc.\DE (VRDN) has 2 years of Preferred Stock Liabilities data on record, last reported at $13.0 million in Q4 2016.

  • For Q4 2016, Preferred Stock Liabilities fell 78.68% year-over-year to $13.0 million; the TTM value through Dec 2016 reached $13.0 million, down 78.68%, while the annual FY2016 figure was $13.0 million, 78.68% down from the prior year.
  • Preferred Stock Liabilities reached $13.0 million in Q4 2016 per VRDN's latest filing, down from $60.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $60.8 million in Q4 2015 and bottomed at $13.0 million in Q4 2016.